RCH 01

Drug Profile

RCH 01

Alternative Names: DSC cell therapy - RepliCel; Hair cell replacement therapy - RepliCel; Human autologous hair follicle cells - RepliCel; RCH-01; RepliCel; RepliCel Hair-01

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RepliCel Life Sciences
  • Developer RepliCel Life Sciences; Shiseido
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Alopecia

Most Recent Events

  • 13 Jun 2017 RepliCel Life Sciences and University of British Columbia enter into a collaboration agreement for the development of RCH-01
  • 25 Apr 2017 RepliCel Life Sciences has patent protection for RCI 02 in USA
  • 14 Mar 2017 Final adverse events data from a phase I/II trial in Alopecia released by RepliCel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top